• News
  • SAN DIEGO
  • BioTech

Neurocrine nets $9.5 million in 4Q

Neurocrine Biosciences Inc. (Nasdaq: NBIX) Friday announced its net income for the fourth quarter of 2012 rose to $9.5 million or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011.

For the year ended Dec. 31, 2012, the Neurocrine reported net income of $5 million, or $0.08 per fully diluted share, as compared to net income of $37.6 million, or $0.67 per fully diluted share, for 2011. One-time milestone payments of $30 million during 2011 were primarily responsible for the change in operating results year over year.

The company's balance sheet at Dec. 31, 2012, reflected total assets of $196 million, including cash, investments and receivables of $188.3 million compared with balances at Dec. 31, 2011 of $138.4 million and $131.7 million, respectively.

During January 2012, the Neurocrine completed a public offering of approximately 10.9 million shares of common stock that resulted in net proceeds of approximately $83 million.

RELATED ARTICLES:

Shire initiates Phase 3 study for patients with rare skin disorders

Bill Walton promotes NuVasive's spinal surgery around country

First patient treated in Genelux's Phase 1 trial

User Response
0 UserComments

Neurocrine Biosciences Inc.

Company Website

12790 El Camino Real
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
NBIX
47.93
  -0.63  
- 1.30%
1,136,515,000
56.97
16.15

Insider Trade Data

Date Insider Shares Type Value
10/16/2015 Bozigian, Haig P 25,000 Sell $1,194,500
10/16/2015 Coughlin, Timothy P 25,000 Sell $1,194,500
10/16/2015 Gano, Kyle 25,000 Sell $1,194,250
10/16/2015 Gorman, Kevin Charles 33,500 Sell $1,600,295
10/16/2015 Grigoriadis, Dimitri E 25,000 Sell $1,194,250

Neurocrine Biosciences Inc. Executive(s):

Kevin Gorman

  • Chief Executive Officer, President

Similar Companies

NAICS - 541711 - Research and Development in Biotechnology